On August 21, 2017, Shire, a biotechnology company focused on developing therapies for rare diseases, announced that chief financial officer (CFO) Jeff Poulton will be leaving the company at the end of the year to serve as CFO at Indigo, a start-up company based in Boston that uses the plant microbiome to improve the productivity and sustainability of agriculture.
Poulton will continue to serve as CFO as the board conducts a formal search for his successor. During this transition period, Poulton will also remain on the company’s executive committee and board of directors, and will continue to support the company’s on-going business review.
“It has been a privilege to work for Shire and to have played a part in the exceptional growth story of such an inspirational company. It has been a difficult decision, but in departing Shire, I wanted to join a smaller organization where I can play a role in building a new company,” said Poulton, in a company press release. “As Shire finalizes the integration of Baxalta and focuses on paying down debt, this also presents a perfect time for me to begin this transition. I know I leave Shire well positioned to pursue its strategy and deliver value for shareholders, supported by a strong Finance team.”
Effective immediately, the company also announced Joanne Cordeiro as their new chief human resources officer and member of the executive committee. She takes over the role previously held by Ginger Gregory. Cordeiro joined Shire in March 2011 and has been serving as interim head of human resources since March 2017.
Source: Shire
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
